PMID- 11316119
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20190817
IS  - 0047-1828 (Print)
IS  - 0047-1828 (Linking)
VI  - 65
IP  - 4
DP  - 2001 Apr
TI  - Plasma monocyte chemoattractant protein-1 antigen levels and the risk of 
      restenosis after coronary stent implantation.
PG  - 261-4
AB  - Monocyte chemoattractant protein-1 (MCP-1) plays a fundamental role in monocyte 
      recruitment and has been implicated in atherosclerosis. The present study tested 
      the hypothesis that increased levels of MCP-1 are associated with an increased 
      risk for restenosis post stent implantation. The plasma MCP-1 antigen levels were 
      measured pre-stenting, and at 24 and 48 h and 6 months post stenting in 41 
      patients with stable exertional angina (SEA) who had undergone successful stent 
      implantation. Nineteen patients with chest pain syndrome were selected as a 
      control group. Initial plasma MCP-1 antigen levels (mean +/- SE, pg/ml) in the 
      patients with SEA were significantly higher than those in the control group 
      (852.3+/-51.4 vs 418.2+/-26.7, p<0.001). The patients with SEA were divided into 
      2 groups based on follow-up angiographic findings: 17 patients with restenosis (R 
      group); 24 patients without restenosis (N group). The lesion was significantly 
      longer in the R group than in the N group (p<0.03). Plasma MCP-1 antigen levels 
      at pre-stenting were not significantly different between the 2 groups 
      (820.6+/-69.1 in the R group vs 874.7+/-73.8 in the N group). Serial changes of 
      plasma MCP-1 levels were plotted as percent changes from the initial levels (mean 
      +/- SE, %) and were significantly higher in the R group than in the N group at 48 
      h and at 6 months post stent implantation (104.6+/-4.8 vs 89.2+/-3.4, p<0.01, 
      109.6+/-11.2 vs 98.5+/-5.0, p<0.05). The study concludes that MCP-1 production at 
      stented coronary arterial sites is associated with an increased risk for 
      restenosis post stent implantation.
FAU - Oshima, S
AU  - Oshima S
AD  - Division of Cardiology, Kumamoto Central Hospital, Japan.
FAU - Ogawa, H
AU  - Ogawa H
FAU - Hokimoto, S
AU  - Hokimoto S
FAU - Nakamura, S
AU  - Nakamura S
FAU - Noda, K
AU  - Noda K
FAU - Saito, T
AU  - Saito T
FAU - Soejima, H
AU  - Soejima H
FAU - Takazoe, K
AU  - Takazoe K
FAU - Ishibashi, F
AU  - Ishibashi F
FAU - Yasue, H
AU  - Yasue H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Jpn Circ J
JT  - Japanese circulation journal
JID - 7806868
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/surgery
MH  - Biomarkers
MH  - Catheterization
MH  - Chemokine CCL2/*blood
MH  - Chest Pain/blood
MH  - Comorbidity
MH  - Coronary Angiography
MH  - Coronary Disease/blood/diagnostic imaging/epidemiology/*therapy
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Risk Factors
MH  - *Stents
MH  - Treatment Outcome
EDAT- 2001/04/24 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/04/24 10:00
PHST- 2001/04/24 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/04/24 10:00 [entrez]
AID - 10.1253/jcj.65.261 [doi]
PST - ppublish
SO  - Jpn Circ J. 2001 Apr;65(4):261-4. doi: 10.1253/jcj.65.261.